This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


December 9 - 10, 2020
Washington, DC

Your Window into Emerging FDA and CMS Regulatory Policies Affecting Life Sciences

The Original Forum for Life Sciences Providing Exclusive Access to FDA/CMS Regulators to Examine Shifting Regulatory and Reimbursement Policy.

Take Advantage of our Advanced Pricing Discount...

Register by August 14, 2020 and Save $300!


As the COVID-19 situation is changing daily, we want you to feel totally confident about booking our events.

What to Expect

Garner the Latest Regulatory Updates and Priorities
  • Hear directly from CDER on goals, trends, new drug development and approvals, & other CDER,  FDA initiatives and developments for 2020 and beyond
  • Discuss the current status of streamlining  the Rare Disease Drug Review Process and the impact of RWE in speeding access to new medicines for rare diseases
  • Explore the shifting regulatory policy landscape for cell and gene therapies
  • Evaluate the future of RWE and PRO in the drug approval process

Examine the Latest Updates to Reimbursement Policies
  • Review CMS updates on changes to policy and new policies regarding the biopharma industry and big pharma
  • Review  reimbursement challenges associated with the rapid growth of novel drugs and high-cost therapies
  • Understand the current state of value- based reimbursement models and value-based outcomes
Changes in the Political and Landscape and Market Trends that Impact Drug Development
  • Drug pricing and affordability and access issues
  • Key entries into the specialty and rare disease pipeline
  • The impact of AI and machine learning on the identification and development of new breakthrough treatments